1. Underuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review 
Isla M. Ogilvie, PhD, Nick Newton, PhD, Sharon A. Welner, PhD, Warren Cowell, MSc, Gregory Y.H. Lip, MD 
The American Journal of Medicine 
Volume 123, Issue 7, Pages e4 (July 2010)
DOI: /j.amjmed
Copyright © 2010 Elsevier Inc. Terms and Conditions

2. Figure 1
Literature search and study inclusion for oral anticoagulation treatment levels. CHADS2=congestive heart failure, hypertension, age >75 years, diabetes mellitus, and prior stroke or transient ischemic attack.
The American Journal of Medicine  , e4DOI: ( /j.amjmed )
Copyright © 2010 Elsevier Inc. Terms and Conditions

3. Figure 2
Patients with atrial fibrillation and prior stroke/transient ischemic attack: oral anticoagulation treatment levels as a proportion of patients eligible for oral anticoagulation therapy.
*Contraindications taken into account.
The American Journal of Medicine  , e4DOI: ( /j.amjmed )
Copyright © 2010 Elsevier Inc. Terms and Conditions

4. Figure 3
Patients with atrial fibrillation at high risk of stroke (CHADS2 score): oral anticoagulant treatment levels as a proportion of patients eligible for therapy.
*Includes patients treated with both oral anticoagulation therapy and antiplatelet therapy.
†Patients defined as having a CHADS2 score of >1 and a bleeding score of <2 (the n value for this population was not available).
CHADS2=congestive heart failure, hypertension, age >75 years, diabetes mellitus, and prior stroke or transient ischemic attack.
The American Journal of Medicine  , e4DOI: ( /j.amjmed )
Copyright © 2010 Elsevier Inc. Terms and Conditions